The KEYVIBE program: vibostolimab and pembrolizumab for the treatment of advanced malignancies

Abstract

Vibostolimab, a humanized IgG1 monoclonal antibody, blocks the interaction between TIGIT and its ligands, preventing the immunosuppressive effects of TIGIT. The addition of vibostolimab to the PD-1 inhibitor pembrolizumab has shown promising antitumor activity, warranting further exploration of vibostolimab as a potential therapeutic option. The KEYVIBE program consists of nine trials that will evaluate the safety and efficacy of vibostolimab monotherapy and vibostolimab-based combination therapy in advanced solid tumors and hematological malignancies. These studies will also evaluate coformulated immunotherapy addressing issues that occur with the sequential administration of immunotherapy. The KEYVIBE program will provide further insight into the clinical utility of vibostolimab-based therapy across multiple indications and various stages of disease.

Trial registration: ClinicalTrials.gov NCT05226598 NCT05224141 NCT05665595.

Keywords: PD-1; TIGIT; clinical trials; hematologic; immunotherapy; pembrolizumab; solid tumors; vibostolimab.

Figure 1.

Mechanism of action of anti-TIGIT antibodies. (A) Interaction of TIGIT with CD155 expressed in tumor cells inactivates T cells, which become exhausted. (B) Antibodies that block TIGIT–CD155 interaction allow for CD226–CD155 interaction, which give the T cell and myeloid cells an activation signal that leads to antitumor activity. Used with permission of Annual Reviews, Inc., from Advances in Therapies Targeting Inhibitory Checkpoint Receptors: TIGIT, LAG-3, and Beyond, Healy JA et al., 8, 2024; permission conveyed through Copyright Clearance Center, Inc.